10-Q/A: Kenilworth Systems Corporation Files Amended Quarterly Report After Financial Restatement

Kenilworth Systems Corporation has filed an amended quarterly report on Form 10-Q/A for the period ended March 31, 2024, to correct financial statements following a restatement in its annual report.

Summary

• Kenilworth Systems Corporation filed an amended quarterly report (Form 10-Q/A) for the period ending March 31, 2024.
• This amendment was necessary due to a restatement of the company's financial statements, which was previously reported in the Annual Report on Form 10-K/A, Amendment No. 2, for the year ended December 31, 2024.
• The company's financials have been corrected throughout Item 1, and certain financial data within the Management Discussion and Analysis of Financial Condition and Results of Operations in Item 2 have also been amended.
• As of March 31, 2024, the company had $4,022 in cash.
• The company reported a net loss of $81,413 for the three months ended March 31, 2024.
• Operating revenue for the quarter was $5,000.
• The company issued 5,950,000 shares of common stock during the quarter, including 4,250,000 shares to directors for services and 1,700,000 shares to investors for $59,500.
• The company's total assets were $52,507, and total liabilities were $81,150 as of March 31, 2024.
• The company has a accumulated deficit of $39,527,513.

Sentiment

Score: 2

Explanation: The document reveals significant financial challenges, including a net loss, low cash reserves, and a substantial accumulated deficit. The company's reliance on future financing and the going concern uncertainty contribute to a negative sentiment.

Positives

• The company is actively reviewing acquisition opportunities in emerging medical and energy technologies.
• Kenilworth is preparing a marketing plan to expand the business operations of its Regenecell subsidiary.
• The company is undergoing a corporate restructuring to focus on its core business and maximize shareholder value.

Negatives

• The company incurred a net loss of $81,413 for the three months ended March 31, 2024.
• The company has an accumulated deficit of $39,527,513.
• The company's current liabilities exceed its current assets.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on generating cash from the sale of its common stock and/or obtaining debt financing.
• There is no assurance that the company will be successful in obtaining financing or achieving its goals.
• The company has a history of net losses and a significant accumulated deficit.
• The company is subject to risks related to its lack of recent operating history and the competitive landscape of its industry.

Future Outlook

The company is exploring acquisition opportunities and plans to expand the business operations of its Regenecell subsidiary. Management intends to protect shareholders and bring the company into a well-run 21st-century company. However, there are no assurances that the company can obtain the necessary financing or achieve these goals.

Management Comments

• Current management, under the guidance of Dan Snyder, has several plans it hopes to put in place.
• Our intentions are to protect the shareholders and Directors and bring the Company into a wellrun 21st century cutting edge company.
• The Companys management team is presently reviewing acquisition opportunities in both the emerging medical technologies field as well as in emerging energy technologies.

Industry Context

The company's focus on emerging medical and energy technologies aligns with current industry trends, but its financial struggles and going concern uncertainty highlight the challenges faced by smaller companies in these sectors. The company's acquisition of Regenecell is a move to diversify and expand its business operations.

Comparison to Industry Standards

• The company's negative earnings per share of $(0.0024) is significantly below industry standards for profitable companies.
• The company's cash position of $4,022 is very low compared to industry benchmarks for companies of similar size.
• The accumulated deficit of $39,527,513 is a significant concern and indicates a history of poor financial performance.
• The company's reliance on equity financing and debt financing to continue as a going concern is not uncommon for early-stage companies, but the lack of assurance of success is a major risk.

Legal Proceedings

• The Company is not currently subject to any legal proceedings.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by the company's restructuring and financial challenges.
• Customers and suppliers may be affected by the company's ability to continue operations.

Next Steps

• The company plans to hold its next Annual Meeting of Shareholders as soon as practicable.
• The company is reviewing acquisition opportunities in emerging medical and energy technologies.
• The company is preparing a marketing plan to expand the business operations of its Regenecell subsidiary.

Key Dates

Keywords

Financial Restatement, Quarterly Report, Form 10-Q/A, Net Loss, Going Concern, Share Issuance, Regenecell, Acquisition, Corporate Restructuring, Financial Statements